Skip to main content
MTEX
NASDAQ Life Sciences

Mannatech Reports Steep Losses, Negative Equity, and Revenue Decline for 2025 Following Delayed 10-K Filing

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$4.96
Mkt Cap
$9.429M
52W Low
$4.665
52W High
$12.454
Market data snapshot near publication time

summarizeSummary

Mannatech reported a significant net loss of $15.2 million for 2025, resulting in negative shareholders' equity, alongside an 8.3% decline in annual net sales and a shift to an operating loss.


check_boxKey Events

  • Significant Net Loss Reported

    The company reported a net loss of $15.2 million, or $8.00 per diluted share, for the full year 2025, a sharp decline from a net income of $2.5 million in 2024. The fourth quarter also saw a net loss of $11.3 million, or $5.94 per diluted share, compared to a net income of $2.3 million in Q4 2024.

  • Shareholders' Equity Turns Negative

    Total shareholders' equity decreased from $8.6 million at the end of 2024 to a negative $5.2 million as of December 31, 2025, primarily due to the substantial net loss.

  • Revenue Decline Continues

    Net sales for 2025 decreased by 8.3% to $108.0 million from $117.9 million in 2024. Fourth-quarter net sales also declined by 8.2% to $26.6 million.

  • Shift to Operating Loss

    Mannatech recorded an operating loss of $0.4 million for the full year 2025, compared to an operating income of $1.4 million in 2024. The fourth quarter also saw an operating loss of $0.2 million.


auto_awesomeAnalysis

Mannatech's 2025 financial results, released via this 8-K and a concurrent 10-K filing, reveal a significant deterioration in financial health. The company reported a substantial net loss for both the fourth quarter and the full year, primarily driven by a large non-cash deferred income tax charge. Critically, the company's shareholders' equity has turned negative, indicating a precarious financial position for this micro-cap company. The ongoing decline in net sales and the shift from operating income to operating loss further underscore the operational challenges. This report follows a previously announced delay in filing the 10-K, which now clarifies the severity of the issues. Investors should be highly concerned about the company's ability to reverse these trends and maintain long-term viability given the negative equity and cash burn.

At the time of this filing, MTEX was trading at $4.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $4.67 to $12.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MTEX - Latest Insights

MTEX
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 24, 2026, 11:55 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
MTEX
Apr 21, 2026, 1:29 PM EDT
Filing Type: DEF 14A
Importance Score:
9
MTEX
Apr 15, 2026, 5:15 PM EDT
Source: Wiseek News
Importance Score:
9
MTEX
Apr 15, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 15, 2026, 5:08 PM EDT
Filing Type: 10-K
Importance Score:
10
MTEX
Apr 01, 2026, 6:47 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 01, 2026, 6:47 PM EDT
Source: GlobeNewswire
Importance Score:
8
MTEX
Mar 24, 2026, 11:36 AM EDT
Filing Type: 8-K
Importance Score:
7